Browse > Article
http://dx.doi.org/10.3904/kjm.2012.83.3.337

A Case of Multiple Tuberculosis Associated with Infliximab Therapy in Crohn's Disease  

Kim, Hee-Wook (Department of Internal Medicine, Yonsei University College of Medicine)
Jang, Sung-Ill (Department of Internal Medicine, Yonsei University College of Medicine)
Kim, Bun (Department of Internal Medicine, Yonsei University College of Medicine)
Youn, Young-Hoon (Department of Internal Medicine, Yonsei University College of Medicine)
Byun, Min-Kwang (Department of Internal Medicine, Yonsei University College of Medicine)
Park, Hyo-Jin (Department of Internal Medicine, Yonsei University College of Medicine)
Lee, Sang-In (Department of Internal Medicine, Yonsei University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.83, no.3, 2012 , pp. 337-341 More about this Journal
Abstract
Infliximab, a tumor necrosis $factor-{\alpha}$($TNF-{\alpha}$) inhibitor, has been approved for the treatment of a variety of inflammatory illnesses, including Crohn's disease. However, infliximab can increase the risk of reactivation of latent tuberculosis (Tbc) infection by affecting host immune responses. Therefore, a screening test should be performed before the initiation of infliximab therapy, and patients with evidence of latent infection should be treated with prophylactic anti-Tbc therapy. Here, we report a case of multifocal disseminated tuberculosis after treatment with infliximab in a patient diagnosed with Crohn's disease who had no past history of Tbc and showed a negative screening test.
Keywords
Infliximab; Tuberculosis; Tumor necrosis $factor-{\alpha}$;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kim SH, Yang SK, Kim KJ, et al. Efficacy of infliximab in the treatment of Korean patients with Crohn's disease. Korean J Gastroenterol 2009;54:108-116.   DOI   ScienceOn
2 Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.   DOI   ScienceOn
3 Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3:148-155.   DOI   ScienceOn
4 Baker D, Clark J, Keenan G, et al. Tuberculosis occurring in patients receiving the anti-TNF-$\alpha$ agent infliximab. Arthritis Rheum 2001;44(Suppl):S105.
5 Kim YH, Lee BJ, Park JJ, et al. Tuberculous meningitis in a patient with Crohn's disease, which was treated with infliximab. Korean J Gastrointest Endosc 2007;34:339-342.
6 Korea Food and Drug Administration. The therapeutic guide-line of latent tuberculosis in trial of anti-TNF agents. 2004:1-6.
7 Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004;2:309-313.   DOI   ScienceOn
8 Kwok SK, Park SH. Guidelines for prevention of tuberculosis in patients with rheumatoid arthritis treated with TNF-alpha blockers. J Korean Rheum Assoc 2007;14: 105-111.   DOI   ScienceOn
9 Garcia Vidal C, Rodríguez Fernandez S, Martinez Lacasa J, et al. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis 2005;40:756-759.   DOI   ScienceOn
10 Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-1132.